🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 21 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 03/01/2013 | 43,70 | 45,30 | 43,31 | 45,15 | +3,44% | 4,55% | 1.841.500 |
| 02/01/2013 | 42,87 | 43,69 | 42,72 | 43,65 | +4,18% | 2,26% | 1.790.600 |
| 31/12/2012 | 40,87 | 42,06 | 40,34 | 41,90 | +2,34% | 4,21% | 1.232.000 |
| 28/12/2012 | 41,38 | 41,85 | 40,94 | 40,94 | -1,96% | 2,20% | 1.026.000 |
| 27/12/2012 | 41,69 | 41,98 | 41,23 | 41,76 | +0,02% | 1,80% | 1.404.600 |
| 26/12/2012 | 42,47 | 42,47 | 41,64 | 41,75 | -1,74% | 1,95% | 844.900 |
| 24/12/2012 | 43,03 | 43,53 | 42,09 | 42,49 | -1,28% | 3,35% | 565.600 |
| 21/12/2012 | 43,00 | 43,48 | 42,39 | 43,04 | -0,69% | 2,53% | 4.115.400 |
| 20/12/2012 | 42,97 | 43,46 | 42,51 | 43,34 | +0,74% | 2,21% | 1.628.100 |
| 19/12/2012 | 42,80 | 44,39 | 42,75 | 43,02 | -0,72% | 3,83% | 3.257.300 |
| 18/12/2012 | 41,92 | 43,37 | 41,92 | 43,33 | +3,64% | 3,46% | 2.017.300 |
| 17/12/2012 | 41,80 | 42,14 | 41,44 | 41,81 | +0,05% | 1,67% | 1.456.400 |
| 14/12/2012 | 41,73 | 42,25 | 41,61 | 41,79 | -0,85% | 1,53% | 1.895.900 |
| 13/12/2012 | 42,06 | 42,61 | 42,02 | 42,15 | -0,24% | 1,40% | 2.680.200 |
| 12/12/2012 | 42,07 | 43,28 | 41,75 | 42,25 | +0,98% | 3,64% | 2.579.200 |
| 11/12/2012 | 40,25 | 41,96 | 40,20 | 41,84 | +3,95% | 4,37% | 2.525.400 |
| 10/12/2012 | 39,12 | 40,31 | 38,67 | 40,25 | +3,52% | 4,19% | 1.792.100 |
| 07/12/2012 | 39,27 | 39,30 | 38,70 | 38,88 | -0,56% | 1,53% | 2.462.900 |
| 06/12/2012 | 39,29 | 39,40 | 38,80 | 39,10 | -0,20% | 1,53% | 1.264.600 |
| 05/12/2012 | 39,63 | 39,65 | 39,12 | 39,18 | -0,79% | 1,34% | 1.308.700 |
| 04/12/2012 | 39,23 | 39,90 | 39,23 | 39,49 | +1,05% | 1,71% | 1.739.600 |
| 03/12/2012 | 39,82 | 40,07 | 38,72 | 39,08 | -1,78% | 3,39% | 1.382.500 |
| 30/11/2012 | 39,74 | 40,17 | 39,56 | 39,79 | +0,13% | 1,53% | 2.331.700 |
| 29/11/2012 | 39,72 | 40,25 | 39,50 | 39,74 | +0,53% | 1,89% | 1.461.700 |
| 28/11/2012 | 38,94 | 39,65 | 38,44 | 39,53 | -1,13% | 3,11% | 2.181.600 |
| 27/11/2012 | 40,66 | 40,74 | 39,85 | 39,98 | -1,28% | 2,19% | 1.754.000 |
| 26/11/2012 | 41,39 | 41,46 | 40,26 | 40,50 | -2,32% | 2,90% | 2.009.100 |
| 23/11/2012 | 41,36 | 41,80 | 41,17 | 41,46 | +0,85% | 1,52% | 544.300 |
| 21/11/2012 | 42,11 | 42,15 | 40,69 | 41,11 | -2,49% | 3,47% | 1.422.300 |
| 20/11/2012 | 41,41 | 42,48 | 41,33 | 42,16 | +1,76% | 2,78% | 2.397.100 |